Director BD (R&D)

• Sep 2022 - Present

LianSn Pharmaceutical, China, was founded in 2003, and headquartered in Beijing. LianSn is a leading pharmaceutical industry group that integrates the entire industry chain of drug innovation, Research & Development, and manufacturing, marketing, and sales of Transdermal Drug Delivery, Oral, Sami solid, and Chinese herbal formulations. • The existing products include; -Oral 12 formulation -5 approvals for TDDS patch formulations -54 approvals for decoction -58 approvals for Chinese herbal drinks Liansheng Pharmaceutical has been rated as a national high-tech enterprise, and actively invests in R&D collaborations with many well-known domestic and overseas research institutes. Obtained 11 national patents, and has obtained 7 international invention patents from the United States and Japan. 1 global first-class new drug is under research. Our focus is cross-border partnering; licensing in /out, acquisition, and Co-Discovery/Co-Development, Please reach out to: asif.xhan@gmail.com asif@liansn.com or my Linkedin to explore more Partnering Opportunities Show less

Snr Manager BD (Scientific Innovation)

• Apr 2021 - Jul 2022

𝐊𝐞𝐲 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬: Ø 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬; • Licence in, acquisition focus on innovative microbiome therapies, innovative Small molecules drugs, Biomedical polymers, and devices. • Independent Searching (based on market insight), Identifying, and initial Evaluation of BD targets, Analysis of data/material • Due diligence and negotiations and completing contract agreements • Preparation or translation of deal materials, such as Confidential disclosure agreement (CDA), Non- Binding term sheet (NBTS), Process Letter, offer letter, Management Presentation, • arrangements of meetings Ø 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐚𝐜𝐚𝐝𝐞𝐦𝐢𝐚 𝐚𝐧𝐝 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐥𝐚𝐛𝐬 𝐏𝐑𝐎𝐉𝐄𝐂𝐓 𝐇𝐈𝐆𝐇𝐋𝐈𝐆𝐇𝐓𝐒: 1- 𝐋𝐢𝐜𝐞𝐧𝐜𝐞 𝐢𝐧 𝐨𝐟 𝐋𝐢𝐯𝐞 𝐁𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬, 𝐁𝐢𝐨𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚, 𝐏𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲, 𝐚𝐧𝐝 𝐄𝐧𝐳𝐲𝐦𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 • Build database of Global Microbiome clinical stage projects • Signed 18 non-disclosure agreements (NDA) • 6 Due diligence • 2 non-binding term sheets (NBTS) 2- 𝐌&𝐀 ; 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐁𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐩𝐨𝐥𝐲𝐦𝐞𝐫 𝐚𝐧𝐝 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 • Searched and screened 65+ companies and products • Signed 2 non-disclosure agreements (NDA) • Signed 1 non-binding indicative offer letter 3- 𝐆𝐥𝐨𝐛𝐚𝐥 𝐭𝐨𝐩 𝐮𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐢𝐞𝐬, 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐜𝐞𝐧𝐭𝐞𝐫𝐬 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬 • Research collaborations Contract with Professor of University of Karolinska Show less

Scientific innovations & BD

• Sep 2019 - Apr 2021

Key Responsibilities:  Involved in the evaluation of BD targets(505 (b) (2), API, FDF) and facilitates due diligence and licensing proposals  Assess potential M&A opportunities  Identifying, forming, negotiating, and completing contract agreements  Market Research Reports (FDF projects)  Deal execution including targets screening/approaching/visiting, communication with targets and clients, analysis of data/material from targets or clients, preparation or translation of deal materials, such as Confidential disclosure agreement (CDA), Non-Binding term sheet (NBTS), Process Letter, Management Presentation, PO, arrangements of meetings, etc.  Assisted API team in cross-border business development PROJECT HIGHLIGHTS 1- Dipharma Francis S.r.l / Italy; Purchase agreement of Triamterene API for FDF 2- Nectar Lifesciences Ltd/ India; Purchase agreement of Cephalosporin antibiotics API for FDF 3- Licence -in Small molecule drugs / Assessed in-license opportunities, Coordinated due diligence and alliance management, ensured the adequate dedication of internal stakeholders to keep projects in good progress, Led or participated in the negotiation of various agreements including confidential disclosure, term sheet, co-development, investment, and licensing contract. 4- Assisted API cross-border team Show less

PSR

• Sep 2010 - Jul 2014

1. Responsible for inflammatory, infection and multivitamin products line. 2. In various types of CME, academic conferences and exhibitions, through satellite meetings, exhibition stands, and other forms of cooperation, to complete product and brand exposure, help products to enhance the brand image in the region. 3. Collaborate with key KOLs, leverage KOL's influence in the region. 4. Use sales tools, combined with data to complete product market analysis. 5. Regular academic meetings and lectures of various types were held, key VIP customers from the region were invited to attend academic meetings and conferences. 6. Established relations with large customers, and for product advantages, have sufficient awareness and ability to conclude sales, can quickly complete the transformation of sales results. 7. Communicate with large customers smoothly, and create relevant opportunities to help customers grow, have strong business negotiation ability and customer control ability, and complete customer development work. Show less

Officer R&D & Regulatory Affairs

• Jan 2009 - Sep 2010

Intern (Pharmaceutical production)

• Nov 2008 - Dec 2008